Vendor Intelligence Report: Aavant Research

Published 3 Jul 2026. 23-page investigative report on who is behind Aavant Research: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Aavant Research is a narrow-strength vendor, not a broadly validated catalog. Across 18 Finnrick lab tests the record is 18 pass / 0 fail and the overall pass rate is 100%. The strength sits in two GLP-1s: Tirzepatide tests as the stronger product, Retatrutide is also favorable, and neither result should be generalized to the 63-product storefront.

The lab story has an important caveat: the report’s methodology-divergence view shows ratings are sensitive to stricter grading, with the concern centered on fill quantity rather than identity failure in the underlying record. For buyers, that makes Aavant more defensible for channel-verified Tirzepatide or Retatrutide than for other products that rely on vendor-posted certificates instead of Finnrick coverage.

The operational file is less clean. The most obvious Aavant domain is returning a Cloudflare 522, while the working storefront has moved to crypto-only payment after earlier evidence showed conventional payment rails. Public U.S. entity and personnel searches did not resolve a named counterparty, and the domain-registration trail does not verify the listed U.S. location.

The highest-severity issue is authentication. The investigation documents multiple Aavant-name surfaces, an unauthenticated Aavant-branded crypto storefront, shared-tagline/contact-infrastructure signals involving Andy Peps Studio, a Telegram release-fee impersonation pattern, and a Telegram bot link promoted from X without independent storefront authentication.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for both Finnrick-covered products
  • Domain and storefront continuity analysis covering aavant.net, aavantpeptides.com, peptide.email, and Base44 App ID
  • Crypto-payment and buyer-recourse timeline from earlier payment rails to the current storefront capture
  • Brand-confusion matrix covering aavantacr.com, Andy Peps Studio, Telegram groups, @DocMike80, and t.me/aavantbot
  • Corporate identity and legal-recourse checks, including U.S. entity searches, personnel search, and WHOIS/location signals
  • July 2026 exhibits for storefront pages, third-party certificates, community warnings, and scam-alert evidence

Risk assessment

  • Brand-confusion and impersonation risk — high: Telegram @DocMike80 scam, dual Aavant Telegram-group warnings, unauthenticated aavantacr.com, and unauthenticated t.me/aavantbot link create material misdelivery/payment-loss risk.
  • Payment-recourse risk from crypto-only checkout — high: Current aavantpeptides.com checkout lists crypto-only payment, removing chargeback-style recourse and making channel authentication decisive.
  • Location and legal-recourse opacity — medium: No public U.S. entity or named personnel were found; aavant.net WHOIS is privacy-shielded in Saint Kitts and Nevis and the storefront discloses China manufacture.
  • Dose-accuracy variability risk for tested GLP-1 products — medium: Tirzepatide and Retatrutide are 18/18 pass, but methodology divergence and field notes indicate fill-quantity sensitivity; do not assume vial labels are exact.
  • Quality-data gap for non-Finnrick-tested catalog products — medium: Finnrick coverage is limited to Tirzepatide and Retatrutide; other listed products, including KPV, BPC-157, TB4 and GHK-CU, rely on vendor-posted third-party certificates.